“…In addition, an EBV molecular classification based on 12 EBV phylopopulations of monophyletic and paraphyletic origins that was obtained by using a Bayesian analysis of the population structure based on the alignments of masked genomes has also been described [ 15 ]. Multiple specific LMP1 variants have been described in benign and malignant EBV-associated diseases have been described but the data on their clinical relevance are still unclear [ 11 , 12 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 ]. The aim of this study was to analyze the distribution of EBV genotypes 1 and 2 as well as EBV LMP1 variant diversity in patients with cHL from the Southeast of Europe in the context of clinical and pathological findings.…”